Grantham, Mayo, Van Otterloo & Co (GMO)
ALXN

Grantham, Mayo, Van Otterloo & Co (GMO)’s Alexion Pharmaceuticals ALXN Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-528,033
Closed -$97M – 792
2021
Q2 		$97M Sell
528,033
-141,290
-21% -$24.3M 0.49% 45
2021
Q1 		$102M Buy
669,323
+397,440
+146% +$61.5M 0.56% 41
2020
Q4 		$42.5M Buy
+271,883
New +$34.9M 0.26% 60
2013
Q3 		– Sell
-69,727
Closed -$6.43M – 704
2013
Q2 		$6.43M Buy
+69,727
New +$6.72M 0.02% 259

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return